


LAW OFFICES
SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, DC 20037-3213
TELEPHONE (202) 293-7060
FACSIMILE (202) 293-7860



May 05, 2000

Assistant Commissioner
of Patents
Washington, D.C. 20231

ATTN: BOX PCT
PCT/AU98/00919
Attorney Docket: Q-59123

Re: Application of William J. LOUIS, Graham P. JACKMAN, Elizabeth L. CONWAY, Andrew L. GUNDLACH, Dimitri IAKOVIDIS, Paul R. KING, Simon N.S. LOUIS and Tracy NERO for "RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS"

Sir:

Please enter the above application into the national stage commencement under Chapter II. Enclosed is a claim to priority and Information Disclosure Statement. It is assumed that copies of the Int'l Application, Int'l Search Report, International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by §371(c) will be supplied directly by the Int'l Bureau, but if copies are needed, please notify the undersigned.

The Government filing fee is calculated as follows:

Total claims	<u>51</u>	-	20	=	<u>31</u>	x	\$18/09	=	\$ 558.00
Independent Claims	<u>12</u>	-	03	=	<u>07</u>	x	\$78/39	=	\$ 702.00
Basic Fee (970/485) or (840/420)								=	\$ 970.00
Multiple Dependent Claim Fee								=	\$ 260.00
Assignment Recordal Fee								=	

TOTAL FILING FEE \$ 2490.00

Attached please find a check in the amount of **\$2490.** for the basic filing fee, excess claim fees and multiple dependent claim fee. You are directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880.

Priority is claimed based on the Australian Patent Appl. No. PP0202/97 filed November 5, 1997. The Int'l. Appl. PCT/AU98/00919 was filed November 5, 1998.

Page -2-
May 05, 2000

The Declaration and Assignment documents will be submitted in due course.

A duplicate copy of this transmittal letter is attached.

Respectfully submitted,



Robert V. Sloan
Reg. No. 22,775

RVS:jlq
Attachments:

001120 20805500

A NOVEL RECEPTOR, AND COMPOUNDS WHICH BIND THERETO

The present invention relates to a novel receptor, in particular to a new type of receptor with an affinity for compounds of the oxazoline class, compounds which bind to this
5 receptor, and the use of these compounds in the treatment of diseases, especially diseases of the central nervous system, the cardiovascular system and the kidney.

Some compounds acting at this receptor were previously thought to be acting at a receptor which was a member of the family of receptors known as imidazoline (I)-receptors. It has
10 now been found that these compounds also act at this novel receptor which is a separate distinct and specific site distinguishable from the known α_2 -adrenoceptors and imidazoline I₁- and I₂-receptors.

Many imidazoline derivatives and structurally-related compounds including oxazolines and
15 guanidines bind not only to α_2 -adrenoceptors but also to I-receptors which differ in structure, function and distribution to α_2 -adrenoceptors (Parini et al, 1996, Regunathan and Reis, 1996). Based on pharmacological studies, the I-receptor binding sites (I-RBS) have been classified into I₁- and I₂-receptor subtypes: an I₁-subtype with a high affinity for [³H]clonidine and an I₂-subtype with a low affinity for clonidine and a high affinity for the
20 imidazoline radioligand, [³H]idazoxan (Parini et al, 1996; Regunathan and Reis, 1996).

I₂-RBS have been usually labelled in tissue membranes or sections using [³H]idazoxan, after masking for α_2 -adrenoceptors, however, recent studies have shown that the new, high affinity radioligand [³H]2-BFI labels I₂-RBS in brain and kidney, and has a greatly enhanced
25 selectivity for I₂-RBS over α_2 -adrenoceptors compared to [³H]idazoxan (Hosseini et al, 1997; Lione et al, 1996). In rat brain the highest densities of I₂-RBS are found in the ependymal layer surrounding the ventricles, the arcuate and interpeduncular nuclei and specific nuclei of the brainstem (Mallard et al, 1995; Tesson et al, 1995). However, moderate levels of binding are also present throughout the cortex, basal ganglia, septum, hippocampus
30 and amygdala (Mallard et al, 1995; Tesson et al, 1995). I₂-RBS have been localised to the outer mitochondrial membrane and in brain appear to be associated with astrocytes

- 2 -


specifically through an association with the mitochondrial enzyme, monoamine oxidase B (MAO-B) (Tesson et al, 1995; Regunathan et al, 1993). A primarily glial localisation of I₂-receptors is further supported by findings that I₂-RBS are present on cultured cortical astrocytes but not neurons (Sastre and Garcia-Sevilla, 1993) and that in human brain I₂-RBS
 5 increase with age, compared to a decline in α_{2A} -adrenoceptors, consistent with known glial hypertrophy and loss of cortical noradrenergic projections (Olmos et al, 1994).

Rilmenidine, an oxazoline, is an antihypertensive drug similar to clonidine but without its pronounced sedative effects. It has been reported as binding to both I₁- and I₂- like receptors
 10 as well as α_2 -adrenoceptors (Parini et al, 1996; Evans, 1996). In some reports its non adrenergic binding has been shown to be atypical to other I compounds (King et al, 1995). However compounds of high specificity for this binding site have now been unexpectedly identified, and this together with a demonstration of specific upregulation of these sites confirm it as neither an I₁- or I₂-receptor site, but as a distinct Oxazoline receptor. It has now
 15 been further established that specific I₁ and I₂-receptor compounds have poor or no detectable activity at the Oxazoline receptor confirming the distinct identity of this site.

The specific physiological upregulation of this new receptor has been demonstrated in the rat hippocampus and its presence has been confirmed in human brain. This receptor
 20 prefers compounds of the oxazoline class and it will be herein referred to as an oxazoline or Ox receptor.

Accordingly in a first aspect of the present invention there is provided a compound of the formula I:

25



I

where R is the residue of an organic compound, X is O or S and Y is a divalent group
 30 making up a 5 or 6 membered ring which compound has a selectivity for the Ox receptor over one or both of the α_2 - and I₂-receptors of greater than 1. Preferably R is connected

- 3 -

to the heterocyclic ring via a divalent bridging group.

Preferably the compound of formula I has a selectivity of greater than 2, more preferably greater than 3, and most preferably greater than 5 over one or more of the α_2 - and I_2 - receptors.

Preferably the compound of formula I has a selectivity of greater than 1, more preferably greater than 2, over both of the α_2 - and I_2 -receptors.

10 It is also preferable that the compound of formula I has a selectivity for the Ox receptor area the I_1 receptor of greater than 1, more preferably greater than 2 and most preferably greater than 3.

The term "selectivity" as used herein refers to the selectivity of a compound for the Ox
15 receptor over another receptor in mammalian tissue containing said receptors. The selectivity is the reciprocal of the ratio of the affinities (in nM) for each receptor site. Preferably the tissue is human tissue.

Preferably the binding affinities for the receptors are as determined using the following
20 ligands.

Ox: ^3H -rilmenidine (preferably in the presence of excess adrenaline to block α -sites).

α_2 : ^3H -methoxyidazoxan

I_2 : ^3H -idazoxan (preferably in the presence of excess adrenaline to block α -sites).

I_1 : ^3H -clonidine (preferably in the presence of excess adrenaline to block α -sites).

- 4 -

Other suitably labelled ligands may also be used.

The Ox receptor is widely distributed in brain, particularly in the pineal gland, cortex, hippocampus, brain stem and spinal cord. In the hippocampus it is found in areas
5 associated with memory, in particular the CA1-CA2 neurons i.e the pyramidal cells. In brain stem and spinal cord, the receptor is found in motor neurons and in brain stem nuclei such as the area postrema, rostroventrolateral medulla, nucleus tractus solitarius and locus coeruleus. These nuclei are associated with regulation of blood pressure. In kidney they are widely distributed in renal cortex and the outer stripe of the outer medulla, sites which
10 are involved in regulation of ion transport. In the adrenal gland they are found in the cortex and the medulla.

Accordingly in a further aspect of the present invention there is provided a method for the treatment or prevention of diseases of the central nervous system, cardiovascular system or
15 the kidney, or diseases associated with abnormal adrenal gland secretion which comprises administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt or ester thereof to a subject in need thereof.

Diseases of the central nervous system include, but are not limited to, dementia, mood
20 disturbances, degenerative conditions, such as stroke or aging, ischaemia, CNS trauma and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Diseases of the cardiovascular system include, but are not limited to, hypertension and ischaemic heart disease.
25

Diseases of the kidney include, but are not limited to, those diseases which affect renal tubular function.

Diseases associated with abnormal adrenal gland secretions include, but are not limited to,
30 hypertension, heart failure and oedema.

The compounds of formula I may also be useful in the treatment of other diseases or

- 5 -


conditions including, but not limited to, hyperglycaemia, glaucoma and peptic ulcer, and may be useful in producing effects such as analgesia.

Accordingly in a further aspect of the present invention there is provided a pharmaceutical composition for the treatment or prevention of diseases of the central nervous system, the cardiovascular system or the kidney, or diseases associated with abnormal adrenal gland secretion which comprises a compound of formula (I) or a pharmaceutically acceptable ester or salt thereof together with a pharmaceutically acceptable carrier or diluent.

- 10 The invention also provides the use of a compound of formula I in the manufacture of a medicament for the treatment or prevention of diseases of the central nervous system, the cardiovascular system or the kidney, or diseases associated with abnormal adrenal gland secretion.
- 15 In yet another aspect of the present invention there is provided the use of a compound of formula I as an agonist or antagonist to the Ox receptor.

In a preferred embodiment the compound of formula (I) is a compound of formula II:

20



W is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally substituted C₁-C₆ alkyl, provided that both of R¹ and R² are not both hydrogen.

30 Z is -NH-, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-,

X is O or S, and

Y is optionally substituted C₂-C₄ alkylene, provided W is not OR' when Z is NH or NHCH₂.

Preferably W is aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); C₅-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); or -CHR¹R² where R¹ and R² are independently selected from hydrogen, C₁-C₆ alkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), C₃-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), and OR where R is aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), C₃-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), or C₁-C₆ alkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); provided R¹ and R² are not both hydrogen.

More preferably W is phenyl or cyclohexyl, naphthyl, each of which may be optionally substituted with one to three substituents selected from hydroxy, methoxy, ethoxy, benzyloxy, NO₂, NH₂, halogen, methyl and ethyl; or -CHR¹R² where R¹ and R² are independently selected from phenyl, naphthyl, cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, methyl, ethyl, propyl and butyl, each of which may be optionally substituted with hydroxy, methoxy, ethoxy, benzyloxy, NO₂, NH₂, halogen, methyl and ethyl; provided R¹ and R² are not both hydrogen.

Preferably Z is imino.

Preferably X is oxygen.


Preferably Y is C₂-C₄ alkylene optionally substituted with C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkanoyloxy or C₁-C₆ alkyloxycarbonyl, or with two substituents which join together to form a 5-6 membered carbocyclic or heterocyclic ring. The carbocyclic or heterocyclic ring may be an optionally substituted, non-aromatic, aromatic or psuedoaromatic ring having 2 to 20 ring atoms.

More preferably, Y is unsubstituted C₂-C₄ alkylene, most preferably unsubstituted ethylene.

10

In another preferred embodiment the compound of formula (I) is a compound of formula III

15



III

wherein R³, R⁴, R⁵ and R⁶ are independently selected from hydrogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl and aryloxy.


Z is imino, C₁-C₂ alkylene, or -CH₂CH₂NH-.

R⁷ and R⁸ are independently selected from hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkanoyloxy or C₁-C₆ alkyloxycarbonyl or R⁷ and R⁸ may together form a 5 or 6 membered aromatic or non-aromatic carbocyclic or heterocyclic ring.

In yet another preferred embodiment the compound of formula (I) is a compound of formula IV:

30


- 8 -



IV

where R^3 , R^4 , R^7 , R^8 and Z are as defined above in relation to formula III.


In yet another preferred embodiment the compound of formula (I) is a compound of formula V:



V

where R^3 , R^4 , R^7 , R^8 and Z are as defined above in relation to formula III and R^9 is C_1 - C_4 alkyl or C_1 - C_4 alkoxy.


In yet another embodiment the compound of formula (I) is a compound of formula VI:



VI

where R^7 , R^8 and Z are as defined above in relation to formula III and R^{10} and R^{11} are independently selected from hydrogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6 cycloalkyl, aryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryloxy.


5 In a further embodiment of the compound of formula (I) is a compound of formula VII:



where R^7 , R^8 and Z are as defined in relation to formula III and R^{12} is hydrogen or optionally substituted C_1 - C_6 alkyl, optionally substituted C_3 - C_7 cycloalkyl or optionally substituted aryl.

15

In another embodiment the compound of formula (I) is a compound of formula VIII:




25 where ϕ is optionally substituted aryl and R^7 , R^8 and Z are as defined above in relation to formula III.

Preferably ϕ is phenyl or naphthyl either of which may have one to four substituents selected from hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6 cycloalkyl, aryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl and aryloxy.


30

In yet another embodiment the compound of formula (I) is a compound of formula IX:



where R^7 , R^8 , Z and ϕ are as defined in relation to formula VIII.

In another embodiment the compound of formula I is a compound of formula X:



15 where R^7 , R^8 , R^{12} and Z are as defined in relation to formula VII and ϕ is defined in formula VIII.

Preferably in formula III to X, Z is -NH- and R^7 and R^8 are hydrogen.

20 The term "aryl" as used herein refers to aromatic rings or ring systems containing between 3 and 20 carbon atoms. The rings or ring systems may be optionally substituted.

25 The term "aromatic rings or ring system" as used herein refers to a compound or substituent which includes or consists of one or more aromatic or pseudoaromatic rings. The rings may be carbocyclic, or heterocyclic, and may be mono or polycyclic ring systems. Examples of suitable rings include but are not limited to benzene, biphenyl, terphenyl, quaterphenyl, naphthalene, tetrahydronaphthalene, 1-benzyl naphthalene, anthracene, dihydroanthracene, benzanthracene, dibenzanthracene, phenanthracene, perylene, pyridine, 4-phenylpyridine, 3-phenylpyridine, thiophene, benzothiophene, naphthothiophene, thianthrene, furan, pyrene, isobenzofuran, chromene, xanthene,

phenoxathin, pyrrole, imidazole, pyrazole, pyrazine, pyrimidine, pyridazine, indazole, indole, indolizine, isoindole, purine, quinoline, isoquinoline, phthalazine, quinoxaline, quinazoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, phenazine, isothiazole, isooxazole, phenoxazine and the like, each of which may be

5 optionally substituted. The term "aromatic rings or ring system" includes molecules, and macromolecules, such as polymers, copolymers and dendrimers which include or consist of one or more aromatic rings. The term "pseudoaromatic" refers to a ring system which is not strictly aromatic, but which is stabilized by means of delocalization of π electrons and behaves in a similar manner to aromatic rings. Examples of pseudoaromatic rings

10 include but are not limited to furan, thiophene, pyrrole and the like.

In this specification "optionally substituted" means that a group may or may not be substituted with one or more non deleterious groups selected from alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy,

15 aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, isocyano, cyano, formyl, carboxyl, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, diarylamino, benzylamino, imino, alkylimine, alkenylimine, alkynylimino, arylimino, benzylimino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, acylamino, diacylamino, acyloxy,

20 alkylsulphonyloxy, arylsulphenyloxy, heterocyclyl, heterocycloxy, heterocyclamino, haloheterocyclyl, alkylsulphenyl, arylsulphenyl, carboalkoxy, carboaryloxy mercapto, alkylthio, benzylthio, acylthio, sulphonamido, sulfanyl, sulfo and phosphorus-containing groups.

25 The term "alkyl" as used herein alone or in compound words such as "alkylester" denotes straight or branched chain alkyl, preferably C_1 - C_{20} alkyl. Examples of straight chain and branched alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, isoamyl, sec-amyl, 1,2-dimethylpropyl, 1,1-dimethyl-propyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 2,2-

30 dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2,-trimethylpropyl, 1,1,2-trimethylpropyl, heptyl, 5-methoxyhexyl, 1-methylhexyl, 2,2-

dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl, octyl, 6-methylheptyl, 1-methylheptyl, 1,1,3,3-tetramethylbutyl, nonyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-methyl-octyl, 1-, 2-, 3-, 4- or 5-ethylheptyl, 1-, 2- or 3-
 5 propylhexyl, decyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- and 8-methylnonyl, 1-, 2-, 3-, 4-, 5- or 6-ethyloctyl, 1-, 2-, 3- or 4-propylheptyl, undecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-methyldecyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-ethylnonyl, 1-, 2-, 3-, 4- or 5-propyloctyl, 1-, 2- or 3-butylheptyl, 1-pentylhexyl, dodecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-methylundecyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-ethyldecyl, 1-, 2-, 3-, 4-, 5- or 6-
 10 propylnonyl, 1-, 2-, 3- or 4-butyloctyl, 1-2-pentylheptyl and the like.

The term "cycloalkyl" as used herein denotes cyclic alkyl groups, including mono- and polycyclic alkyl groups. Examples of cyclic alkyl include mono- or polycyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
 15 cyclononyl, cyclodecyl and the like. Preferably the cyclic alkyl groups are C₃-C₆ alkyl groups such as cyclopentyl and cyclohexyl. Examples of cyclic alkyl also including heterocyclic forms containing one of oxygen, sulphur and nitrogen atoms such as tetrahydropyran, tetrahydrofuran, pyrimidines, pyridazines, oxazines and related compounds.

20

The term "alkoxy" denotes straight chain or branched alkoxy, preferably C₁₋₂₀ alkoxy. Examples of alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy and the different butoxy isomers.

25 The term "alkenyl" denotes groups formed from straight chain, branched or cyclic alkenes including ethylenically mono-, di- or poly-unsaturated alkyl or cycloalkyl groups as previously defined, preferably C₂₋₂₀ alkenyl. Examples of alkenyl include vinyl, allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3-heptenyl, 1-
 30 octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-

butadienyl, 1-4,pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl and 1,3,5,7-cyclooctatetraenyl.

- 5 The term "alkynyl" denotes groups formed from straight chain, branched or cyclic alkyne including alkyl and cycloalkyl groups as previously defined which contain a triple bond, preferably C₂₋₂₀ alkynyl. Examples of alkynyl include ethynyl, 2,3-propynyl and 2,3- or 3,4-butynyl.
- 10 The term "acyl" either alone or in compound words such as "acyloxy", "acylthio", "acylamino" or "diacylamino" denotes carbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl or a heterocyclic ring which is referred to as heterocyclic acyl, preferably C₁₋₂₀ acyl. Examples of acyl include carbamoyl; straight chain or branched alkanoyl such as formyl, acetyl, propanoyl,
- 15 butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl and icosanoyl; alkoxy carbonyl such as methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl and heptyloxycarbonyl; cycloalkyl carbonyl such as
- 20 cyclopropyl carbonyl, cyclobutyl carbonyl, cyclopentyl carbonyl and cyclohexyl carbonyl; alkylsulfonyl such as methylsulfonyl and ethylsulfonyl; alkoxy sulfonyl such as methoxy sulfonyl and ethoxy sulfonyl; aroyl such as benzoyl, toluoyl and naphthoyl; aralkanoyl such as phenylalkanoyl (e.g. phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutyl, phenylpentanoyl and phenylhexanoyl) and naphthylalkanoyl (e.g.
- 25 naphthylacetyl, naphthylpropanoyl and naphthylbutanoyl; aralkenoyl such as phenylalkenoyl (e.g. phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl and phenylhexenoyl and naphthylalkenoyl (e.g. naphthylpropenoyl, naphthylbutenoyl and naphthylpentenoyl); aralkoxy carbonyl such as phenylalkoxy carbonyl (e.g. benzyloxycarbonyl); aryloxy carbonyl such as phenoxy carbonyl and

naphthyloxycarbonyl; aryloxyalkanoyl such as phenoxyacetyl and phenoxypropionyl; arylcarbamoyl such as phenylcarbamoyl; arylthiocarbamoyl such as phenylthiocarbamoyl; arylglyoxyloyl such as phenylglyoxyloyl and naphthylglyoxyloyl; arylsulfonyl such as phenylsulfonyl and naphthylsulfonyl; heterocycliccarbonyl; heterocyclicalkanoyl such as thienylacetyl, thienylpropanoyl, thienylbutanoyl, thienylpentanoyl, thienylhexanoyl, thiazolylacetyl, thiadiazolylacetyl and tetrazolylacetyl; heterocyclicalkenoyl such as heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl and heterocyclichexenoyl; and heterocyclicglyoxyloyl such as thiazolylglyoxyloyl and thienylglyoxyloyl.

10

The term "heterocyclic" as used herein refers to aromatic, pseudo-aromatic and non-aromatic rings or ring systems which contain one or more heteroatoms selected from N, S and O and which may be optionally substituted. Preferably the rings or ring systems have 3 to 20 carbon atoms.

15

Where a carbon is asymmetrically substituted and optical isomers exist for compounds of formula I it has been found that the optical isomers vary in their affinity and selectivity for the Ox receptor and α_2 -adrenoceptor's as much as 100-fold.


20 Free base forms of the compounds of the invention may be converted into the acid addition salts in a conventional manner and vice versa. Suitable acids for addition salts include, hydrochloric, tartaric, malonic and fumaric.

In the compounds of the invention the carbon atom next to Z may be asymmetrically

25 substituted as may the carbons of the oxazoline ring. The compounds may be prepared as racemic mixtures or the isomers may be isolated in the conventional manner from asymmetric starting materials or by resolution of the base on fractional crystallisation with optically active acids.

30 A compound of formula I, where X is O, Y is CH_2CH_2 , and R is connected to the

heterocyclic ring via a bridging group -NH-, may be prepared in two steps by converting the appropriate primary amine into an oxazoline via the chloroethyl urea.



5 Other compounds may be prepared in analogous manner.

Some of the compounds of formula I are novel and represent a further aspect of the present invention.

10 Some compounds of formula II and III are known and are excluded from this further aspect of the invention.

Compounds with the general formulae III and V where Z is -NH-, R⁵, R⁶, R⁷ and R⁸ are H, R³ is lower alkyl of 1 to 3 carbon atoms and R⁴ and R⁹ are independently H or a lower alkyl of 1 to 5 carbon atoms have been previously disclosed in US3598833 and US5034406 to be useful in the following therapeutic areas: reducing or maintaining intra-ocular pressure, for example in the treatment of glaucoma; increasing blood-sugar levels, for example in the treatment of hyperglycemia; inhibiting gastric-secretion, for example in the treatment of ulcers and hypertonia; vasoconstriction; depressing blood pressure; sedation; local anesthesia

and hypertension.

Compounds with the general formula II where Z is -NH-, X is O, Y is -CH₂CH₂- and W is CHR¹R² where R¹ and R² can each independently be H (but not both H), or a low molecular weight alkyl group substituted with an optionally substituted cyclopropyl have been previously disclosed in US3988464 and US4102890 to be useful in the following therapeutic areas: in treating hypertension; treating heart failure and edematous disease; analgesia; depressing the cardiovascular system; neuromodulation; lowering blood pressure; treating cardiovascular diseases; treating neuropsychological disturbances; depression of the CNS which may result in hypnosis, analgesic action and or antipsychotic effects.

Compounds with the general formula II where Z is -NH-, X is O, Y is -CH₂CH₂- and W is CHR¹R² where R¹ can be a haloalkyl of 1 to 3 carbon atoms and R² can be a lower alkyl radical having 1 to 6 carbon atoms in a straight or branched chain, a lower cycloalkyl radical having from 3 to 7 carbon atoms which may be substituted by one or more lower alkyl radicals, or lower alkoxy radicals have been previously disclosed in US4378366 and DE4325491 to be useful in the following therapeutic areas: in treating hypertension; treating acute alterations in intermediary metabolism subsequent to surgery, trauma and burns.

Compounds with the general formula II where Z is -NH-, X is O, Y is -CH₂CH₂- and W is CHR¹R² where R₁ can be a haloalkyl of 1 to 3 carbon atoms and R₂ can be an optionally substituted phenyl or furanyl or thiophene or pyrrole group have been previously disclosed in US4267345 to be useful as antihypertensive agents.

The compound with the general formula II where Z is -NH-, X is O, Y is -CH₂CH₂- and W is CHR¹R² where R¹ and R² are cyclopropyl groups has been previously disclosed in patents US5605911, US5459133 and DE4325491 to be useful in the following therapeutic areas: treating post aggression syndrome, preventing neurotoxic side-effects when administered with an NMDA antagonist; combatting a naturally occurring form of NMDA-receptor hypofunction which occurs as a causative or aggravating mechanism in people suffering from

schizophrenia; reduction of at least one neurotoxic side effect selected from the group consisting of formation of vacuoles in neurons in cerebrocortical or limbic brain regions, expression of heat shock proteins in cerebrocortical or limbic brain regions, alteration or loss of mitochondria in neurons, neuronal death or hallucinations and psychotomimetic effects;

5 increasing the accommodative ability of the eye for the purpose of decreasing the severity of presbyopia.

Homogenate binding studies have shown that I₂-RBS increase with age in human brain, consistent with glial hypertrophy. In autoradiographic studies we have compared the spatial

10 relationship of I₂-RBS and Ox receptor sites and astrocytes in young and aged rats. At a level through the rostral hippocampus [³H]2-BFI (a specific I₂-receptor ligand) binding was not altered in the brain of 24 month-old rats compared to 3 month-old rats, although GFAP mRNA levels were elevated throughout both white and grey matter areas. Unexpectedly there was a dramatic difference in the pattern of Ox receptors. Binding to this receptor in the

15 pyramidal cell layer of the CA1-CA3 region of the hippocampus was more prominent in the aged rats and there was a marked concentration of binding over the CA2 region. Additional binding was evident in layer 3 of the parietal cortex, the ventromedial and dorsomedial hypothalamic nuclei and the medial amygdaloid nuclei in the aged animals. This binding pattern distinct from that of GFAP mRNA suggests the binding is localised to neurons rather

20 than to glial cells and provides further evidence of a distinct neuronal receptor site that is physiologically upregulated.

Short periods of global cerebral ischaemia induce selective neuronal loss in the CA1 field of the hippocampus in experimental models in animals and in humans after cardiac arrest (Petito

25 et al, 1990). This delayed neuronal death has been widely studied in the rat four-vessel occlusion (4-VO) model and is accompanied by a reactive astrocytosis involving cell hypertrophy and hyperplasia and transformation of GFAP-negative into GFAP-positive glia that persist for some weeks post-ischaemia (Gustafson et al, 1990). It was originally hypothesised that I₂-RBS might be linked to this altered expression of GFAP, however, it was

30 found when examining the spatial relationship of changes in I₂-RBS and reactive gliosis following 4-VO ischaemic injury in rats the pattern of binding of the selective I₂-RBS ligand,

[³H]2-BFI, was unaltered. Unexpectedly, specific binding to Ox receptors was increased by approximately 60%, 4 and 8 days after the ischaemic insult but had returned to normal levels at later time points. This increase was observed only in the CA1 pyramidal cell region of the hippocampus and was not related to reactive astrocytosis and was localized to neuronal cell bodies. The upregulation of Ox receptors following ischaemia demonstrates for the first time that these Ox sites are involved in pathophysiological processes in the brain which appear to represent compensatory mechanisms in surviving neurons and provide a rationale for use of compounds which act at these sites as neuroprotective agents. The changes in Ox receptors also provide further evidence that the Ox receptor is a novel receptor site, distinct from I₂-receptors and α₂-adrenoceptors.

The Ox receptor pharmacophore as depicted by formula I differs from those of the I₂-receptor (Nero et al, 1997) and α₂-adrenoceptor (Timmermans and van Zwieten, 1977) in the nature of the bridging moiety Z and the hydrogen bond donor (or acceptor) groups (-NH- and X). For both the Ox receptor and α₂-adrenoceptor pharmacophores the bridging moiety Z induces a bend into the molecular configuration, whereas in the I₂-receptor pharmacophore Z, typically a bond, maintains an overall linear molecular configuration. The nature of the hydrogen bond donor (or acceptor) groups further differentiates the Ox receptor pharmacophore from the I₂-receptor pharmacophore in that compounds containing an imidazoline ring (where X is NH) have poor (μM) affinity at the Ox receptor binding site and high (nM) affinity at the I₂-RBS. While compounds containing an oxazoline ring (X is O) have high affinity (nM) for the Ox receptor binding site and poor (μM) affinity at the I₂-RBS. The Ox receptor pharmacophore can be further distinguished from the α₂-adrenoceptor pharmacophore by the substituents R₅ and R₆ as present in formula III. Substitutions in this region of the compound reduce, or abolish, α₂-adrenoceptor affinity while maintaining affinity for the Ox receptor.

While it is possible that, for use in therapy, compounds of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a composition. The composition may be a pharmaceutical composition.

The invention thus further provides pharmaceutical compositions comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

For some formulations it may be preferable to prevent the active compound in the form of a pharmaceutically acceptable salt or ester.

10 Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2-sulphonate, salicylate and the acetate. Such salts, and pharmaceutically
15 acceptable esters, are formed by procedures well known in the art.

Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.

20

Pharmaceutical compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.

25

The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for
30 oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in

conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing one (1) milligrams of active ingredient or, more broadly, 0.001 to three hundred 5 (300) milligrams, per tablet, are accordingly suitable representative unit dosage forms.

The compounds of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention 10 or a pharmaceutically acceptable salt of a compound of the invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A 15 solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided 20 active component.

In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

25 The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "pharmaceutical composition" is intended to include the formulation of the active compound 30 with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.

Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, prefilled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins,

- 22 -

methycellulose, sodium carboxymethylcellulose, or other well known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.

Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane,

- 23 -

trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

- 5 Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or
10 blister packs from which the powder may be administered by means of an inhaler.

- In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for
15 example by micronization.

When desired, formulations adapted to give sustained release of the active ingredient may be employed.

- 20 The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it
25 can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

- 30 A further aspect of the present invention contemplates an isolated Ox receptor

- 24 -

polypeptide.

Preferably, the isolated Ox receptor polypeptide is in a sequencably pure form.

- 5 By "sequencably pure" is meant that the purified Ox receptor is provided in a form which is sufficiently homogeneous and, if necessary, modified to facilitate amino acid sequence determination.

10 The isolated Ox receptor may be characterised by a high binding affinity for O501 and a poor binding affinity for methoxyidazoxan, clonidine and idazoxan. Preferably the receptor is characterised by having a binding affinity for O501 of 1 to 500 nM and affinities for methoxyidazoxan, clonidine and idazoxan of greater than 1000. More preferably the receptor is characterised by having a binding affinity for O501 is between 10 and 100 nM and affinities for methoxyidazoxan, clonidine and idazoxan is greater than 15 5000 nM.

Standard methods may be used to isolate the Ox receptor polypeptide for example gel filtration, ion-exchange chromatography, hydrophobic interaction chromatography, reverse-phase chromatography, electrophoresis, affinity chromatography or immuno- 20 affinity chromatography, amongst others or any combination thereof. Such methods are well-known to those skilled in the art and the use of all such methods to isolate an Ox receptor polypeptide are encompassed by the present invention.

In one preferred embodiment, the receptor can be identified by expression cloning by 25 screening of commercially available cDNA libraries expressed in bacterial or mammalian cells. Preferred sources of these libraries are rat hippocampus and rat kidney. Positive clones expressing the Ox receptor are identified by screening for binding of tritiated rilmenidine or other suitably labelled oxazoline, in the presence of sufficient idazoxan (1 μ M), moxonidine (220 nM) and 2-BFI (220 nM) to inhibit binding to the α_2 , I₁ and I₂

- 25 -

receptors. Positive clones are selected and rescreened until single positive clones can be identified. cDNA from these clones is isolated and sequenced using standard techniques. The resulting cDNA sequence can be used to infer the corresponding amino acid sequence for the receptor.

5

In another preferred embodiment, the Ox receptor polypeptide is isolated using at least one affinity chromatography step, optionally in association with one or more other procedures for protein purification. As will be known to those skilled in the art, the isolation of an Ox receptor polypeptide using affinity chromatography requires a
10 biospecific ligand capable of specifically binding to the intact Ox receptor or an Ox receptor polypeptide to be attached to a chromatographic matrix for example Sepharose™, Superose™, cellulose or Sephacryl™ (Pharmacia Fine Chemicals, Uppsala, Sweden), amongst others such that the immobilised ligand retains its specific binding affinity for the Ox receptor or Ox receptor polypeptide.

15

Preferably, the biospecific ligand is a chemical compound which exhibits specific and reversible binding affinity for the intact Ox receptor or an Ox receptor polypeptide.

Particularly preferred biospecific ligands contemplated by the invention include Ox
20 receptor substrate compounds and substrate analogues, such as those described herein. More preferably, the biospecific ligand is a compound having the structure set forth in formula II, even more preferably a compound having the structure set forth in Formula II, which allows it to be attached to the chromatographic matrix.

25 The biospecific ligand is attached to the chromatographic matrix either directly or alternatively, *via* a spacer arm placed therebetween, for example a spacer arm comprising a short alkyl group having between 1 and 12 carbon atoms, to reduce steric interference between the matrix and the Ox receptor. Standard covalent coupling procedures may be employed, for example coupling via cyanogen bromide, carbodiimide, epoxy, thiopropyl,

- 26 -

diazonium or bromoacetamidoalkyl groups, amongst others.

The Ox receptor in cellular extract or a derivative fraction thereof in a suitable "binding buffer", is applied to the affinity chromatography column under conditions sufficient to
5 promote binding of the receptor to the column. The non-specific binding of molecules other than Ox receptors may be minimised by including in the binding buffer one or more chemical compounds for which said molecules have a high binding affinity compared to the Ox receptor. Alternatively, or in addition, the binding buffer may include one or more protease inhibitors, serine protease inhibitors, trypsin inhibitors, leupeptin or PMSF,
10 to minimise proteolysis of the Ox receptor during the isolation step. Once the Ox receptor is bound to the column, the column is washed several times with binding buffer to remove contaminants.

The bound Ox receptor may be eluted from the affinity matrix using a variety of elution
15 methods known to those skilled in the art. Elution methods may be either selective or non-selective in nature. Usually, selective elution methods are applied in combination with group specific adsorbents and non-selective elution methods are used in combination with highly specific adsorbents. A compromise may have to be made between the harshness of the eluent required for elution and the risk of denaturing the eluted material.
20 Forces which maintain the complex include electrostatic interactions, hydrophobic effects and hydrogen-bonding. Agents which weaken these interactions may be expected to function as efficient eluting agents. Elution may be achieved by either a step-wise or a continuous change in conditions. Continuous gradients are useful for their zone sharpening effect; the trailing edge of a desorbed substance experiences a higher
25 concentration of eluting agent than the peak and is therefore made to move faster down the column than the main peak. When substances are very tightly bound to the adsorbent, it may be effective to stop the flow after applying eluent and to allow the adsorbent to remain in the presence of eluting agent (30 min to 2h is commonly used) before commencing elution. This allows dissociation to take place prior to elution and thus

- 27 -

ensures good recoveries of adsorbed substances.

Changes in pH, ionic strength, polarity or the use of denaturing agents such as chaotropic salts, guanidine-HCl or urea or electrophoretic techniques may be used to desorb the
5 bound Ox receptor or Ox receptor polypeptide from the affinity matrix.

Alternatively, the Ox receptor or Ox receptor polypeptide may be desorbed using a selective eluent capable of competing for the binding of the receptor or receptor polypeptide to the ligand. The selective eluent may be applied to the column in a suitable
10 buffer composition at a single concentration or a concentration gradient of the eluent in the buffer may be used.

In a particularly preferred embodiment the Ox receptor or Ox receptor polypeptide is eluted using a selective eluent comprising O501.
15

The isolated Ox receptor polypeptide is provided in a sequencably pure form by any means of preparing proteins for amino acid sequence determination known to those skilled in the art. Preferably, the polypeptide is purified using at least one chromatographic or electrophoretic step.
20

Whilst the N-terminus of the isolated Ox receptor polypeptide may be sequenced, it is particularly desirable to obtain internal amino acid sequences of the Ox receptor polypeptide. Accordingly, a sequencably pure Ox receptor polypeptide will preferably comprise a proteolytic digestion product of the complete Ox receptor polypeptide,
25 obtained for example by digestion of the isolated polypeptide with trypsin and/or endo-lysC. As with the isolated protein, the peptides obtained by proteolytic digestion are further purified to facilitate their amino acid sequence determination.

Peptides are generally transferred to PVDF membranes to facilitate the sequence

- 28 -

determination of nanomolar quantities or even femtomolar quantities of peptide, and sequenced using Edman degradation or other techniques known to those skilled in the art.

The amino acid sequence of the Ox receptor polypeptide is useful for the preparation of
5 degenerate pools of synthetic oligonucleotides encoding same or complementary thereto.

Those skilled in the art will be aware that such oligonucleotide pools are particularly useful as hybridisation probes and/or amplification primers in the isolation of nucleic acid molecules which encode the Ox receptor polypeptide described herein. In preparing
10 oligonucleotide pools for such purposes, it is desirable to utilise those amino acid sequences of peptides which include one or more amino acid selected from the list comprising phenylalanine, tryptophan, tyrosine, cysteine, histidine, glutamine, asparagine, lysine, aspartate or glutamate or alternatively, which include no more than one amino acid selected from the list comprising leucine, serine and arginine. Selection of
15 amino acid sequences in accordance with these parameters reduced the number of different oligonucleotide sequences which are required to provide a representative pool including all possible Ox receptor polypeptide-encoding sequences.

The oligonucleotides described herein will at least comprise a combination of any of the
20 nucleotides adenine, cytidine, guanine, thymidine, or inosine, or functional analogues or derivatives thereof which are at least capable of being incorporated into a polynucleotide molecule without having an inhibitory effect on their use as hybridisation probes or primer molecules.

25 Furthermore, one or both of the nucleic acid primer molecules may be contained in an aqueous mixture of other nucleic acid primer molecules, for example a mixture of degenerate primer sequences which vary from each other by one or more nucleotide substitutions or deletions. Alternatively, one or both of the nucleic acid primer molecules may be in a substantially pure form.

- 29 -

The oligonucleotide sequences derived from isolated Ox receptor peptide sequences are employed to identify and isolate Ox receptor-encoding nucleotide sequences from cells, tissues, or organ types of any mammalian species which expresses an Ox receptor, in particular a laboratory mammal such as a rat, mouse or rabbit.

In one approach, genomic DNA, or mRNA, or cDNA derived from the cells, tissues or organs of said mammal, in particular kidney tissue, is contacted with a hybridisation effective amount of one or more oligonucleotide pools described herein or a complementary sequence and then the hybridising genomic DNA, or mRNA, or cDNA is detected.

In a particularly preferred embodiment, the Ox receptor-encoding oligonucleotide is end-labelled with a reporter molecule capable of giving an identifiable signal (e.g. a radioisotope such as ^{32}P or ^{35}S or a biotinylated molecule).

The hybridising genetic sequence thus identified is preferably in a recombinant form, in a virus particle, bacteriophage particle, yeast cell, animal cell, or a plant cell.

An alternative method contemplated in the present invention involves hybridising two nucleic acid "primer molecules" derived from the Ox receptor peptide amino acid sequence described herein to a nucleic acid "template molecule" comprising an Ox receptor-encoding gene or a part thereof. According to this embodiment, specific nucleic acid molecule copies of the template molecule are amplified enzymatically in a polymerase chain reaction, a technique that is well known to one skilled in the art.

In a preferred embodiment, each nucleic acid primer molecule is at least 10 nucleotides in length, more preferably at least 20 nucleotides in length, even more preferably at least 30 nucleotides in length, still more preferably at least 40 nucleotides in length and even still

- 30 -

more preferably at least 50 nucleotides in length.

The nucleic acid template molecule may be in a recombinant form, in a virus particle, bacteriophage particle, yeast cell, animal cell, or a plant cell. Preferably, the nucleic acid
5 template molecule is derived from a human or laboratory animal species.

Those skilled in the art will be aware that there are many known variations of the basic polymerase chain reaction procedure (McPherson *et al*, 1991). The present invention extends to the use of all such variations in the isolation of Ox receptor-encoding genetic
10 sequences.

The isolated nucleic acid molecule which encodes the Ox receptor polypeptide or a functional part thereof may be cloned into a plasmid or bacteriophage molecule, such as for the production of recombinant gene products. Methods for the production of such
15 recombinant plasmids, cosmids, bacteriophage molecules or other recombinant molecules are well-known to those of ordinary skill in the art and can be accomplished without undue experimentation. Accordingly, the invention further extends to any recombinant plasmid, bacteriophage, cosmid or other recombinant molecule comprising the nucleic acid molecules described herein.

20 Still yet another aspect of the invention contemplates a method of identifying a modulator of Ox receptor activity, said method comprising assaying recombinant Ox receptor activity in the presence of a potential modulator and comparing said activity to the activity of recombinant Ox receptor in the absence of said potential modulator.

25 As used herein, the term "modulator" shall be taken to refer to any chemical compound, molecule or macromolecule which is capable of altering the activity of an Ox receptor polypeptide, in particular a mammalian Ox receptor polypeptide, including both agonists and antagonists of said activity.

- 31 -

Preferably, the subject method further comprises the first step of expressing a functional recombinant Ox receptor polypeptide in a cell for a time and under conditions sufficient for said polypeptide to be produced in an assayable quantity.

- 5 The term "assayable quantity" refers to a level of expression of a recombinant polypeptide which is sufficient for the activity of said polypeptide to be determined by any standard assay procedure which is specific for the function of the recombinant polypeptide.

- 10 A further aspect of the invention contemplates a modulator of Ox receptor activity, such as a competitive or non-competitive inhibitor, a competitive or non-competitive activator molecule or a molecule which binds irreversibly to an Ox receptor without leading to activation thereof or alternatively, an antibody molecule or catalytic antibody molecule capable of binding and inhibiting the activity of a Ox receptor polypeptide, amongst others.

- 15 Preferably, the modulator is one which is identified using the method described *supra* for the identification of modulators of Ox receptor activity.

- 20 The modulator molecules described herein are useful in a wide range of prophylactic and therapeutic applications, by virtue of their ability to agonise or antagonise Ox receptor activity. Antagonists are particularly useful in the treatment of physiological or medical conditions wherein Ox receptor activity is elevated or it is desirable to reduce Ox receptor activity, whilst agonists are useful in the treatment of any conditions associated with reduced Ox receptor activity or where it is desirable to increase Ox receptor activity.

- 25 In order to facilitate an understanding of the invention reference will be made to the following examples which illustrate some preferred embodiments of the invention and demonstrate that the Ox receptor is a new receptor, distinct from I_2 receptors and α_2 -adrenoceptors. However it is to be understood that the particularity of the following

- 32 -

description is not to supersede the generality of the preceding description of the invention.

Example 1

- 5 a) **1-Dicyclohexylmethylamino-3-chloroethyl urea:** Chloroethyl isocyanate (11g in 16 ml of tetrahydrofuran) is added dropwise into a solution of dicyclohexylmethylamine (19.5g in 125ml of tetrahydrofuran). After 2hrs the precipitated solid is filtered, washed with tetrahydrofuran and air-dried. Yield= 23.4g, 78%.
- 10 b) **2-(Dicyclohexylmethylamino)-oxazoline) (O503):** 1-Dicyclohexylmethylamino-3-chloroethyl urea, 36.1g, finely powdered is suspended in 75ml water. Sufficient tetrahydrofuran is then added to dissolve the solid followed by a 10% solution of aqueous sodium hydroxide (26ml). After refluxing for 1hr the solvent is removed under reduced pressure. The residue is extracted with ethyl acetate. The extracts are washed with brine, dried over sodium sulfate and evaporated to dryness. The residue is recrystallised from ethyl acetate:hexane. m.p. = 135-138°C Yield = 9.45g, 59%. Proton nmr spectrum in deuterated chloroform shows δ 0.6-2.0 (22H broad doublet, cyclohexyl protons), δ 3.2-4.2 (5H m, oxazoline and methine protons), δ 4.7 (1H s, NH). Chemical ionisation mass spectrum shows MH⁺ ion at m/e 265.
- 15
- 20

Example 2

- 25 a) **(R)-(-)-1-(1-Cyclohexylethyl)-3-chloroethyl urea:** Chloroethyl isocyanate (11g in 16 ml of tetrahydrofuran) is added dropwise into a solution of (R)-(-)-1-(1-cyclohexylethylamine (12.7g in 125ml of tetrahydrofuran). After 2hrs the precipitated solid is filtered, washed with tetrahydrofuran and air-dried. Yield = 15.3g, 75%. m.p. = 109-113°C.

- 33 -

- b) **(R)-(-)-2-(1-Cyclohexylethylamino)-oxazoline ((R)-(-)-O504)** : (R)-(-)-1-(1-Cyclohexylethyl)-3-chloroethyl urea, 13.7g, finely powdered is suspended in 75ml water. Sufficient tetrahydrofuran is then added to dissolve the solid followed by a 10% solution of aqueous sodium hydroxide (26ml). After refluxing for 1hr the solvent is removed under reduced pressure. The residue is extracted with ethyl acetate. The extracts are washed with brine, dried over sodium sulfate and evaporated to dryness. The residue is recrystallised from ethyl acetate:hexane, m.p. = 76-79°C. Yield = 7.6g, 58%. Proton nmr spectrum in deuterated chloroform shows 8.0-1.9 (11H bd, cyclohexyl protons), δ 1.07 (3H d, methyl protons), δ 3.5-4.3 (4H m, oxazoline protons), δ 3.4 (1H q, methine proton), δ 4.5 (1H s, NH). Chemical ionisation mass spectrum shows MH⁺ ion at m/e 197.

Example 3

- a) **(S)-(+)-1-(1-Cyclohexylethyl)-3-chloroethyl urea**: Chloroethyl isocyanate (11g in 16 ml of tetrahydrofuran) is added dropwise into a solution of (S)-(+)-1-(1-cyclohexylethylamine (12.7g in 125ml of tetrahydrofuran). After 2hrs the precipitated solid is filtered, washed with tetrahydrofuran and air-dried. Yield = 15.5g, 76%, m.p. = 107-110°C.
- b) **(S)-(+)-2-(1-Cyclohexylethylamino)-oxazoline ((S)-(+)-O504)** : (S)-(+)-1-(1-Cyclohexylethyl)-3-chloroethyl urea, 13.7g, finely powdered is suspended in 75ml water. Sufficient tetrahydrofuran is then added to dissolve the solid followed by a 10% solution of aqueous sodium hydroxide (26ml). After refluxing for 1hr the solvent is removed under reduced pressure. The residue is extracted with ethyl acetate. The extracts are washed with brine, dried over sodium sulfate and evaporated to dryness. The residue is recrystallised from ethyl acetate:hexane, m.p. = 70-75°C. Yield = 7.4g, 56%. Proton nmr spectrum in deuterated chloroform shows δ 0.9-2.0 (11H bd, cyclohexyl protons), δ 1.1 (3H d, methyl protons), δ 3.5-4.2 (4H m, oxazoline protons), δ 3.4 (1H q, methine proton), δ 4.5 (1H s,

- 34 -

NH). Chemical ionisation mass spectrum shows MH⁺ ion at m/e 197.

Example 45 a) **(R)-2-(1-(4-nitrophenyl))ethylaminooxazoline (R-O505NO₂).**

(R)- α -methyl-4-nitrobenzylamine hydrochloride (645 mg, 0.32 mmole) was suspended in 5 ml tetrahydrofuran and stirred with triethylamine (330 mg) for 1 hour. 2-chloroethylisocyanate (360 mg, 95%) was added in 5 ml tetrahydrofuran with stirring and the mixture stirred for 4 hours. 6 ml of water was then added followed by 2 ml 10 molar sodium hydroxide and the mixture heated to reflux for 24 hours. The mixture was then diluted with 50 ml ethyl acetate and shaken. The aqueous phase was discarded and the organic layer washed with 5 ml water, then extracted twice with 5 ml 1 molar hydrochloric acid. The extracts were combined and basified with 10 molar sodium hydroxide. The precipitated product was extracted with 25 ml ethyl acetate, washed with water and then reduced to dryness in vacuo. The product forms pale yellow crystals on drying, mp. 112-116°C. Yield 0.62 g (83%). Proton nmr in CDCl₃ shows 7.8 (4H dd, J=9 and 42Hz), 4.8 (1Hq, J=7Hz), 3.9 (4Hm) 1.4(3H d, J=7Hz).

20 b) **(R)-2-(1-(4-aminophenyl))ethylaminooxazoline (R-O505NH₂).**

(R)-2-(1-(4-nitrophenyl))ethylaminooxazoline (600 mg) was dissolved in 5 ml 1 molar hydrochloric acid and stirred with powdered tin (400 mg) After 2 hours the solution was basified with sodium hydroxide and extracted with ethyl acetate (50 ml). The extract was washed twice with water (10 ml) and reduced to dryness in vacuo. The product was a colourless oil 500 mg. Proton nmr in CDCl₃, 6.8 (4Hq), 4.6 (1H q, J=7Hz) 3.9(4H m), 1.4 (3Hd, J=7Hz).

c) **2-(4-hydroxyphenyl)ethylaminooxazoline. (O508)**

Tyramine hydrochloride (1.04g) was stirred in 5 ml tetrahydrofuran with triethylamine 860 μ l for 16 hours, after which 2-chloroethylisocyanate (540 μ l)

- 35 -

was added and stirring continued for 24 hours. The mixture was extracted into ethyl acetate and washed with 1M hydrochloric acid (10 ml) and water, before reducing to dryness in vacuo. The residue was redissolved in tetrahydrofuran (5ml) and water (5 ml) containing sodium sulfite (50 mg). 5 molar sodium hydroxide (2 ml) was added and the mixture heated to reflux for 5 hours. Sodium dihydrogen phosphate (1g was then added with stirring) and the mixture reduced to dryness in vacuo. The product was isolated by extraction with chloroform (10 ml) and isopropanol (2 x 10 ml). The combined extracts were reduced to dryness and reconstituted in ethyl acetate containing 10% methanol. The mixture was separated by chromatography on silica gel, and eluted with mixtures of ethyl acetate and methanol. The combined eluates were reduced to dryness to give a crystalline solid (450 mg, 35%), mp. 90-96°C. Proton nmr in deuterated methanol shows, 6.7 (4H q), 4.5- 3.0 (6H m) 2.5 (2H br.tr., J=8Hz). Chemical ionisation mass spectrum shows m/e 207 (MH+).

d) **2-(4-benzyloxyphenyl)propylaminooxazoline. (O509)**

4-benzyloxyphenylethylamine 1.256g was dissolved in 10 ml tetrahydrofuran, 2-chloroethylisocyanate (0.55g) was added and stirred for 16 hours. 5 ml % molar sodium hydroxide was then added and the mixture heated to reflux for 5 hours. On cooling, ethyl acetate 50 ml was added and the aqueous fraction discarded. The organic phase was washed twice with water (10 ml) then extracted with 10 ml 1 molar hydrochloric acid. The extract was basified with sodium hydroxide, and the precipitated solid extracted with ethyl acetate (50 ml). The extracts were washed with water then reduced to dryness in vacuo. Yield 800 mg (50%) of a white crystalline solid, mp 34-47°C Proton nmr in CDCl₃. 7.3 (5Hs), 6.8 (4H q,), 4.9 (2Hs), 3.9 (6H br m), 2.6 (2H br.d., J=6Hz), 1.05 (3H tr, J=7Hz). Chemical ionisation mass spectrum shows m/e 311 (MH+).

e) **2-phenoxyethylaminooxazoline (O510)**

2-phenoxyethylamine (0.714g) was dissolved in 10 ml tetrahydrofuran and 2-

- 36 -

chloroethylisocyanate (0.55g) was added with stirring. After 4 hours at room temperature 2 ml of 10% sodium hydroxide was added and the mixture heated to reflux for 5 hours. The solution was extracted into ethyl acetate (50 ml), washed with water (10 ml), then extracted into 10 ml 1 molar hydrochloric acid. This extract was basified with sodium hydroxide and reextracted into ethyl acetate (25 ml). The extract was washed with water and reduced to dryness leaving a white waxy crystalline solid. Proton nmr in CDCl_3 δ 7.0 (5H m), δ 3.4-4.4 (8H m). Chemical ionisation mass spectrum shows m/e 207 (MH+).

10 f) **2-(4-methoxyphenoxy)ethylaminooxazoline (O511)**

2-(4-methoxyphenoxy)ethylamine (0.871g) was dissolved in 10 ml tetrahydrofuran and 2-chloroethylisocyanate (0.55g) was added with stirring. After 4 hours at room temperature 2 ml of 10% sodium hydroxide was added and the mixture heated to reflux for 5 hours. The solution was extracted into ethyl acetate (50 ml), washed with water (10 ml), then extracted into 10 ml 1 molar hydrochloric acid. This extract was basified with sodium hydroxide and reextracted into ethyl acetate (25 ml). The extract was washed with water and reduced to dryness leaving a white waxy crystalline solid. Proton nmr in CDCl_3 δ 6.9 (4H s), δ 3.4-4.4 (8H m) δ 3.8 (3H s). Chemical ionisation mass spectrum shows m/e 237 (MH+).

The compounds prepared above are represented in Table 1 below together with selectivity data where available.

Table 1

Compound	Formula	R7, R8	Z	Φ	R12	Selectivity Ox/apha2
(R)-O505-NO ₂	X	H	NH	4-nitrophenyl	CH ₃	
(R)-O505-NH ₂	X	H	NH	4-aminophenyl	CH ₃	
O508	VIII	H	CH ₂ CH ₂ NH	4-hydroxyphenyl		100

- 37 -

25	Compound	Formula	R7, R8	Z	Φ	R12	Selectivity Ox/αpha2
	O509	VIII	H	CH ₂ CH ₂ NH	4-benzyloxyphenyl		2.0
	O510	VIII	H	CH ₂ CH ₂ NH	phenoxy		
	O511	VIII	H	CH ₂ CH ₂ NH	4-methoxyphenoxy		

5

Example 5**Receptor Affinities and Selectivities of Selected Drugs for Ox receptors, α₂-adrenoceptors and I₂-receptors in Rat Brain Homogenates**

10

The following compounds were tested for their affinities and selectivities for Ox, I₂ and α₂-receptors in brain homogenates.

Table 2

15	Compound	Formula*	R₁	R₂	R₃	R₄	R₁₀	R₁₁	R₁₂
	Rilmenidine	II	cyclopropyl	cyclopropyl	-	-	-	-	-
	BAY-A6781	III	-	-	methyl	ethyl	-	-	-
	(+)-S8349	II	CF ₃	cyclopropyl	-	-	-	-	-
	(-)-S8350	II	CF ₃	cyclopropyl	-	-	-	-	-
20	O501	III	-	-	ethyl	ethyl	-	-	-
	O502	II	phenyl	phenyl	-	-	-	-	-
	O503	VI	-	-	-	-	H	H	-
	(S)-(+)-O504	VII	-	-	-	-	-	-	methyl
	(R)-(-)-O504	VII	-	-	-	-	-	-	methyl
25	(S)-(-)-O506	II	methyl	1-naphthyl	-	-	-	-	-

*where X is O, Y is -CH₂CH₂-, Z is NH and, for formula II, W is -CHR¹R², for formula III R⁵ and R⁶ are hydrogen, and for formulae III, VI and VII R⁷ and R⁸ are H.

Methoxyidazoxan is 2-(2-methoxy-1,4-benzodioxan)-imidazoline); clonidine is 2-(2,6-

30 dichlorophenylamino)-imidazoline; idazoxan is 2-(1,4-benzodioxan)-imidazoline; cirazoline is 2-(2-cyclopropylphenoxyethyl)-imidazoline; BU-224 is 2-(4,5-dihydroimidaz-2-

- 38 -

yl)quinoline.

The results are shown below in Tables 3 and 4.

5

Table 3

	Compound	Receptor Affinities (nM)		
		Ox	I ₂	Selectivity Ox/I ₂ *
	Methoxydazoxan	319,000	24,400	0.08
10	Clonidine	7030	5270	0.7
	Idazoxan	62,300	2.3	0.00004
	Cirazoline	21,200	1.6	0.00008
	BU-224	>100,000	0.9	<0.000009
15				
	Rilmenidine	15	36	2.4
	O501	18	6,900	383
	O502	160	1,900	12
	O503	117	3,800	32
20	(S)-(+)-O504	106	707	6.7
	(R)-(-)-O504	31	56	1.8

*Compounds more selective for the Ox site have a selectivity > 1

Table 4

25	Compound	Receptor Affinities (nM)		
		Ox	α_2	Selectivity Ox/ α_2 *
	Methoxydazoxan	319,000	1.9	0.000006
	Clonidine	7030	2.7	0.0004
30				
	Idazoxan	62,300	15.6	0.0003

- 39 -

Cirazoline	21,200	2.6	0.0001
BU-224	>100,000	5,477	<0.1
Rilmenidine	15	410	27
O501	18	210	12
O502	160	380	2.4
O503	117	640	5.5
(S)-(+)-O504	20	30	1.5
(R)-(-)-O504	32	590	18

*Compounds more selective for the Ox site have selectivity of > 1

The affinity and selectivity of the claimed compounds in the rat is exemplified by comparisons with conventional ligands in Tables 3 and 4, in which selectivity is defined as the reciprocal of the ratio of the affinities in nanomolar concentrations for each site.

15

In the rat, selective α_2 -adrenoceptor antagonists such as methoxyidazoxan exhibit poor affinity (μM) for both the Ox receptor and the I_2 -receptor and high affinity (nM) for the α_2 -adrenoceptor. Such a binding pattern indicates that the Ox receptor and I_2 -receptors are distinct sites from the α_2 -adrenoceptors. Clonidine, which has been reported widely to be an I_1 and α_2 -receptor ligand, also displays poor affinity (μM) for both the Ox receptor and I_2 -receptor and high affinity (nM) for α_2 -adrenoceptors, indicating that both Ox receptors and I_2 -receptors are binding sites distinct from the I_1 - and α_2 -receptors. Known I_2 -receptor ligands, such as idazoxan, cirazoline and BU-224, display poor (μM) affinity for the Ox receptor and high affinity (nM) for the I_2 -receptor, consistent with being highly selective I_2 ligands. This indicates that the Ox receptor and I_2 -receptor are distinct. The I_2 -receptor ligands idazoxan and cirazoline also have a high affinity (nM) for α_2 -adrenoceptors, whereas BU-224 has poor affinity (μM) for this receptor. The oxazoline rilmenidine is a known α_2 -adrenoceptor agonist which has a high affinity (nM) for both the Ox receptor and the I_2 -receptor in the rat but lower affinity in human brains.

30

- 40 -

Example 6**Receptor Affinities and Selectivities of Selected Drugs for Ox receptors and I₂-receptors in Human Brain Homogenates.**

- 5 The following compounds were also tested for their affinities and selectivities for Ox receptors and I₂- receptors in human brain homogenates. The results are shown in Table 5.

Table 5

10	Compound	Receptor Affinities (nM)		
		Ox	I ₂	Selectivity Ox/I ₂
	Methoxydiazoxan	100,000	>100,000	1
	Clonidine	17,930	18,460	1.0
15	Idazoxan	6060	4.8	0.0008
	Cirazoline	1074	1.6	0.0015
	BU-224	9576	2.2	0.0002
	BAY-A6781	215	8,250	38
20	Rilmenidine	396	5,220	13
	(+)-S8349	268	13,000	49
	(-)-S8350	199	7,700	32
	O501	38	9,100	239
	O502	234	686	3
25	O503	70	4,800	69
	(S)-(+)-O504	180	2,190	12
	(R)-(-)-O504	300	2,700	9
	(S)-(-)-O506	99	7,580	77

*Compounds with selectivity > 1 show significant selectivity for the Ox receptor.

30

In humans, all of the oxazolines tested displayed significant selectivity (3-239) for the Ox receptor over the I₂-receptor.

- 41 -

Measurement of the affinity and selectivity of such compounds for the α_2 -adrenoceptor, I_2 -receptor and Ox receptor binding sites may be carried out by either of two procedures, i.e. ligand displacement studies in membranes of brain and kidney or by autoradiography of brain and kidney sections. In both cases the radioligand is tritiated rilmenidine ($[^3H]$ -RIL).

- 5 Rilmenidine is an oxazoline compound, which is an effective anti-hypertensive agent and originally believed to act as a central and peripheral α_2 -adrenoceptor agonist. As rilmenidine not only binds to α_2 -adrenoceptor sites but also in the rat to I -receptors, Ox receptor sites may be preferentially labelled by incubation with $[^3H]$ -RIL in the presence of μM concentrations of α_2 -adrenoceptor ligands such as adrenaline or methoxyidazoxan with or
- 10 without the addition of the I_1 - and I_2 -receptor ligands clonidine and idazoxan. Analysis of the displacement of $[^3H]$ -RIL from these sites by drugs reveals the affinity of the drug for each binding site.

RECEPTOR BINDING STUDIES

15 Brain Membrane preparation

- Male WKY rats are stunned and decapitated. The brains are removed and the forebrain dissected free, then frozen over liquid nitrogen before being stored at $-70^\circ C$. Human brain cortex samples are obtained within 28 hours of death and frozen over liquid nitrogen before being stored at $-70^\circ C$. On the day of the measurement the cortex (human or rat) is
- 20 homogenised in 20 vol ice-cold 50 mM Tris.HCl buffer (pH 7.4) using a Polytron tissue homogeniser. The homogenate is centrifuged at $37000 \times g$ for 10 min and the pellet resuspended in 20 vol of fresh buffer and recentrifuged. The pellet is then resuspended in 33 vol of 50mM Tris.HCl buffer for use in binding assays. Where adrenaline is used in binding assays the buffer also contains $25\mu M$ EDTA and $10 \mu M$ pargyline.

25

Measurement of Ox receptor binding sites

- Drug inhibition of $[^3H]$ -RIL ($38-49 \text{ Ci/mmol}$) binding is measured in duplicate in samples containing $5nM$ $[^3H]$ -RIL and competing drug $0.01nM$ to $10mM$, $10\mu M$ adrenaline and $15mg$ of membranes in a final volume of $1ml$. After incubation for 30 min at $25^\circ C$, the
- 30 membranes are recovered by filtration onto Whatman GF/B glass fibre filters presoaked in

- 42 -

1.0% polyethyleneimine. The filters are washed 3 times with cold assay buffer before measurement of bound radioactivity by scintillation counting. The binding data are analysed by an iterative non-linear computerised curve fitting program "RADLIG" version 4.0 (McPherson, 1983).

5

Measurement of α_2 -adrenoceptor and I_2 -receptor binding sites

Brain membranes prepared as above, are incubated in the presence of [3 H]-methoxyidazoxan (52 - 57 Ci/mmol) 0.5nM or [3 H]-idazoxan (43-45Ci/mmol) 1.6nM in Tris.HCl buffer pH 7.4 for α_2 -adrenoceptor and I_2 -receptor binding respectively. Inhibition of binding is measured in the presence of increasing amounts of test compound (0.1nM to 1mM). Non-specific binding is estimated by addition of 10 μ M phentolamine or 100 μ M cirazoline respectively. Membrane bound radioactivity is isolated and measured as above by vacuum filtration, washing and scintillation counting. Data is analysed by the "RADLIG" program.

15 AUTORADIOGRAPHIC STUDIES

Preparation of tissue sections

Male WKY rats are stunned and decapitated. The brains, kidneys or spinal cords are rapidly excised, frozen over liquid nitrogen and stored at -70°C until used. The tissues are then mounted onto microtome chucks with Tissue-Tek embedding matrix. Horizontal, coronal or sagittal sections are cut (10 to 14 μ m thick) at -15°C and thaw mounted onto cold gelatine/chrome alum coated slides. 2 to 4 sections are mounted on each slide, air-dried at room temperature, then stored with silica gel dessicant at -70°C up to 2 weeks before use.

Measurement of O_x receptor binding sites in tissue sections

The mounted sections are brought to room temperature and preincubated for 20 min in 50mM Tris.HCl buffer (pH 7.6) to remove endogenous inhibitors such as noradrenaline. The slides are then dried at room temperature. Each section is then covered with the same buffer containing 40nM [3 H]-RIL \pm 1 μ M adrenaline or 10 μ M of the oxazoline BAY A6781 and incubated at room temperature for 60 min to assess total, non-adrenergic and non-specific binding respectively. Breakdown of adrenaline is minimised by addition of 25 μ M EDTA and

- 43 -

10µM pargyline. The incubations are terminated by washing the sections in fresh buffer for 4 min and rinsing in distilled water. Sections are then air-dried and desiccated overnight. The sections are then apposed to tritium sensitive (Hyperfilm™ -³H, Amersham) film in X-ray cassettes for 4 to 16 weeks at 4°C. After exposure the films are developed in Kodak D19 at 5 18 to 20°C for 5 min. Autoradiograms are analysed by computer aided densitometry and calibrated by co-exposed tritium standards.

Example 7

Method for isolating novel receptors:

- 10 Rat hippocampus and rat kidney cDNA libraries are available from Stratagene. The libraries are prepared in the Lambda ZAP® II vector cloning system.

Bacteriophage are plated at approximately 40, 000 pfu/plate with the appropriate E.coli strain on 150 mm LB agar plates, using 7ml of 1% top agar. The plates are incubated for 2-4 hours 15 at 37°C until plaques are pinpoint size. Protein expression is then induced by overlaying plaques with filters saturated with IPTG (isopropyl theogalactosidase) (soaked in 10mM solution and dried at RT). Plates and filters are then incubated for a further 8-12 hours until plaques are approximately 1mm in size.

- 20 After one hour at 4°C the orientation of each filter is marked asymmetrically and lifted. Filters are then air dried for 5 minutes at RT. Plaques are overlayed with a duplicate set of IPTG-soaked filters, and then induced as for first set. Filters are blocked at room temperature for 30 minutes in 50nM Tris pH 7.6 with 10µM adrenaline and 100 nM idazoxan. 5nM ³H-Rilmenidine or other radiolabelled ligand is added and this is incubated 25 for 2-24 hours at 4°C in a heat sealed bag on a rotating platform. Filters are washed 4-5 times in blocking buffer for 5-10 minutes at 4°C. Filters are then blot dried, and exposed to tritium sensitive x-ray film (Hyperfilm TM-3H, Amersham) at -70°C.

- Positive phage clones are picked from the plates using the autoradiograms, and 30 secondary/tertiary screens performed until an individual clone or clones are obtained.

- 44 -

The cloned DNA-phasemid is then released by co-infection with helper phage to generate sub-clones for plasmid DNA preparation and subsequent DNA sequencing, by dideoxynucleotide chain terminating sequencing.

5 Example 7

Method of isolating and sequencing the Oxazoline receptor

A tissue rich in Ox receptors, such as rabbit kidney, is homogenised in 10 mM Tris buffer containing 5 mM EGTA, 5 mM EDTA and 10 μ M phenylmethylsulfonyl fluoride pH7.4 at 4°C. The homogenate is subjected to differential centrifugation to isolate the plasma membrane fraction. The protein is solubilised with buffer containing octylglucoside detergent and purified by affinity chromatography with a column of sepharose coupled to a ligand such as formula II where X is O, Y is -CHR⁵CHR⁶- where R⁵ and R⁶ are H, W is -CHR¹R² wherein R₁ is 4-amino,2-methoxyphenyl, R₂ is H and Z is NH. Binding of α_2 -adrenoceptors and I-receptors to the column can be minimised by the addition of methoxyidazoxan and 2-BFI, and the Ox-receptor selectively eluted with buffer containing O501. The eluate is then dialysed against drug-free buffer to remove O501. The Ox receptors in the eluate are selectively labelled with a photoaffinity label such as (¹²⁵I)-AZIPI (Lanier et al, 1995) or related compounds derived from formula II where X is O, Y is -CHR⁵CHR⁶- where R⁵ and R⁶ are H, W is -CHR¹R² wherein R¹ is 4-amino, 2-methoxyphenyl, R₂ is H and Z is NH; by exposure to ultraviolet light. The labelled Ox receptors are then precipitated with trichloroacetic acid, washed with ether and solubilised in Laemmli loading buffer and electrophoresed on 10% polyacrylamide gel under denaturing conditions. After electrophoresis, the gels are dried under vacuum and exposed to X-ray film for 1 to 8 days. The labelled bands can be located after development of the X-ray films and transferred electrophoretically to polyvinylidene difluoride membranes. The areas corresponding to the labelled Ox receptors are cut out and digested with trypsin. The generated peptides can then be separated by microbore reversed phase high performance liquid chromatography and the amino acid sequence of each determined. These sequences can then be used as the basis for generation of oligonucleotide probes for the dna sequence of the Ox receptor.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

10 understood to imply the inclusion of a stated integer or step or group of integers or steps but
not the exclusion of any other integer or step or group of integers or steps.

- 46 -

REFERENCES

- Alemaný R, Olmos G, Escriba PV, Menargues A, Obach R and Garcia-Sevilla JA. LSL 60101, a selective ligand for imidazoline I-2 receptors, on glial fibrillary acidic protein concentration. Eur. J. Pharmacol. 1995; 280, 205-210.
- Evans RG Current status of putative imidazoline (I₁) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Clin. Exp. Pharmacol. Physiol. 1996; 23: 845-854.
- Gustafson I, Westerberg, E. and Wieloch, T. Protection against ischemia-induced neuronal damage by α_2 -adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 1990; 10, 885-894.
- Hosseini R, King PR, Louis WJ and Gundlach AL. [³H]2-(2-benzofuranyl)-2-imidazoline, a highly selective radioligand for I₂-imidazoline receptor binding sites: Studies in rabbit kidney membranes. Naun.-Schmied. Arch. Pharmacol. 1997; 355:131-138.
- King PR, Gundlach AL and Louis WJ. Quantitative autoradiographic localization in rat brain of α_2 -adrenoceptors and non-adrenergic I-receptor binding sites labelled by [³H] rilmenidine. Brain Res. 1995; 675, 264-278.
- Lanier B, Raddatz R, Bakthavachalam V, Couprie I, Neumeyer JL and Lanier SM. Structural and Ligand Recognition Properties of Imidazoline Binding Proteins in Tissues of Rat and Rabbit. Mol. Pharmacol. 1995; 48: 703-710.
- Lione LA, Nutt DJ and Hudson L. [³H]2-(2-Benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I₂ receptors. Eur. J. Pharmacol. 1996; 304, 221-229.

- 47 -

Mallard NJ, Hudson AL and Nutt DJ Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. *Br. J. Pharmacol.* 1992; 106, 1019-1027.

- 5 McPherson, GA A practical computer-based approach to the analysis of radioligand binding experiments. *Comput. Programs Biomed.* 1983; 17: 107-113.

McPherson, M.J., Quirke, P. and Taylor, G.R. (1991) *PCR A Practical Approach*. IRL Press, Oxford University Press, Oxford, United Kingdom.

10

Nero TL, Hosseini AR, King PR, Iakovidis D, Gundlach AL and Louis WJ. Development of an I₂-receptor pharmacophore, presented at the International Workshop on Imidazoline Receptors, September 10, 1997, Melbourne, Victoria, Australia (Satellite Meeting to the International Society of Autonomic Neurosciences 1997), p44 of the conference handbook.

15

Olmos G, Alemany R, Escriba PV and Garcia-Sevilla JA. The effects of chronic imidazoline drug treatment on glial fibrillary protein concentrations in rat brain. *Br. J. Pharmacol.* 1994; 111, 997-1002.

- 20 Parini A, Moudanos CG, Pizzinat N and Lanier SM. The Elusive Family of Imidazoline Binding Sites. *TIPS* 1996; 17: 13-16.

Petito CK, Morgello S, Felix JC and Lesser ML. The two patterns of reactive astrocytosis in postischemic rat brain. *J. Cereb. Blood Flow Metab.* 1990; 10, 850-859.

25

Regunathan S, Feinstein DL and Reis DJ. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. *Neurosci. Res.* 1993; 34: 681-688.

Regunathan S and Reis DJ. Imidazoline receptors and their endogenous ligands. *Annu. Rev.*

- 30 *Pharmac. Toxicol.* 1996; 36: 51-44.

Sastre M and Garcia-Sevilla JA. Opposite age-dependent changes of α_{2A} -adrenoceptors and [3H]Idazoxan binding sites (I_2 -imidazoline sites) in the human brain: strong correlation of I_2 with MAO-B sites. J. Neurochem. 1993; 61: 881-889.

- 5 Tesson F, Limon-Boulez I, Urban P, Puype M, Vandekerckhove J, Couprie I, Pompou D and Parini A. Localisation of I₂-Imidazoline Binding Sites on Monoamine Oxidases. J. Biol. Chem. 1995; 270: 9856-9861.

Timmermans, PBWM and van Zwieten PA. QSAR in centrally acting imidazolines
10 structurally related to clonidine. J. Med. Chem. 1977; 20: 1636-1645.

- 49 -


THE CLAIMS.

1. An isolated Ox receptor in sequencably pure form.
- 5 2. An isolated Ox receptor characterised by a high binding affinity for O501 and a poor binding affinity for methoxyidazoxan, clonidine and idazoxan.
3. An isolated Ox receptor characterised by having a binding affinity for O501 of 1 to 500 nM and affinities for methoxyidazoxan, clonidine and idazoxan of greater than 1000.
- 10 4. A receptor according to claim 3 characterised by having a binding affinity for O501 is between 10 and 100 nM and affinities for methoxyidazoxan, clonidine and idazoxan is greater than 5000 nM.
- 15 5. An isolated nucleic acid molecule which encodes an Ox receptor as claimed in any one of claims 1 to 4.
6. A recombinant plasmid, cosmid, bacteriophage or other recombinant molecule comprising a nucleic acid molecule according to claim 5.
- 20 7. A method for identifying a modulator or Ox receptor activity, said method comprising assaying recombinant Ox receptor activity in the presence of a potential modulator and comparing said activity to the activity of recombinant Ox receptor in the absence of said potential modulator.
- 25 8. A method according to claim 7 wherein the recombinant Ox receptor is obtained by expressing a functional recombinant Ox receptor polypeptide in a cell for a time and under conditions sufficient for said polypeptide to be produced in an assayable quantity.

30

- 50 -

9. Use of a compound of the formula I:




5

where R is the residue of an organic compound, X is O or S and Y is a divalent group making up a 5 or 6 membered ring, which compound has a selectivity for an Ox receptor over one or both of the α_2 - and I_2 - receptors of greater than 1, as an agonist or antagonist to the Ox receptor.

10

10. A method for modulating the activity of an Ox receptor including the step of applying to a source of Ox receptor an effective amount of a compound of formula I:




15

where R is the residue of an organic compound, X is O or S and Y is a divalent group making up a 5 or 6 membered ring, which compound has a selectivity for an Ox receptor over one or both of the α_2 - and I_2 - receptors of greater than 1.

20

11. A compound having a selectivity for an Ox receptor over one or both of the α_2 - and I_2 -receptors of greater than 1, which is a compound of formula II



25

wherein W is optionally substituted aryl, optionally substituted C_5 - C_7 cycloalkyl or - CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1 - C_6 alkyl, optionally substituted C_3 - C_7 cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C_3 - C_7 cycloalkyl or

30

- 51 -

optionally substituted C_1 - C_6 alkyl, provided that of R^1 and R^2 are not both hydrogen, Z is imino, C_1 - C_2 alkylene, $-CH_2NH-$ or $-CH_2CH_2NH-$, X is O or S, and Y is optionally substituted C_2 - C_3 alkylene, provided that W is not OR' when Z is imino or $-CH_2NH-$; and with the further provisos that

- 5 a) when Y is CH_2CH_2 , X is O and Z is imino then
- (i) W is not unsubstituted or 2-mono-, 2,2-di, 2,5-di, 2,6-di or 2,4,6-tri C_{1-3} alkyl substituted cyclohexyl or 2-mono- or 2,5-di C_{1-3} alkyl substituted cyclopentyl or 2- C_{1-3} alkyl substituted cycloheptyl; and
- (ii) if W is CHR^1R^2 and R^1 is H then R^2 is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethylphenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and
- (iii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^1 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and
- 10 15 b) when Y is $(CH_2)_{2,4}$, X is O or S, Z is imino and W is CHR^1R^2 , then
- (i) if R^1 is CF_3 , CF_2CF_3 or $CF_2CF_2CF_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and
- (ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;
- 20 or a pharmaceutically acceptable ester or salt thereof.

12. A compound of claim 11 wherein W is aryl (optionally substituted with hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6 cycloalkyl, aryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl or aryloxy); C_5 - C_6 cycloalkyl (optionally substituted with

25 hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6

- 52 -

- cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); or -CHR¹R² where R¹ and R² are independently selected from hydrogen, C₁-C₆ alkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), C₃-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), and OR' where R' is aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), C₃-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), or C₁-C₆ alkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy);
- 15 provided R¹ and R² are not both hydrogen.

13. A compound of claim 11 or claim 12 where W is phenyl or cyclohexyl, naphthyl, each of which may be optionally substituted with one to three substituents selected from hydroxy, methoxy, ethoxy, benzyloxy, NO₂, NH₂, halogen, methyl and ethyl; or -CHR¹R² where R¹ and R² are independently selected from phenyl, naphthyl, cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, methyl, ethyl, propyl and butyl, each of which may be optionally substituted with hydroxy, methoxy, ethoxy, benzyloxy, NO₂, NH₂, halogen, methyl and ethyl, provided R¹ and R² are not both hydrogen.

- 25 14. A compound of any one of claims 11 to 13 wherein Z is imino or -CH₂CH₂NH-.

15. A compound of any one of claims 11 to 14 wherein X is oxygen.

16. A compound of any one of claims 11 to 15 wherein Y is C₂-C₃ alkylene optionally substituted with C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkanoyloxy or C₁-C₆ alkyloxycarbonyl, or with two substituents which join together to form a 5-6 numbered


- 53 -

carbocyclic or heterocyclic ring.

17. A compound of claim 16 wherein Y is unsubstituted C₂-C₄alkylene.


5 18. A compound of claim 17 wherein Y is ethylene.

19. A compound according to claim 11 which is a compound of formula III:



15 wherein R³, R⁴, R⁵ and R⁶ are independently selected from hydrogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryloxy, Z is imino, C₁-C₂ alkylene, or -CH₂CH₂NH-, R⁷ and R⁸ are independently selected from hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkanoyloxy or C₁-C₆ alkyloxycarbonyl or R⁷ and R⁸ may together form a 5 or 6
20 membered aromatic or non-aromatic carbocyclic or heterocyclic ring.


20. A compound according to claim 11 which is a compound of formula IV:



30 where R³, R⁴, R⁷, R⁸ and Z are as defined in claim 19.

- 54 -


21. A compound according to claim 11 which is a compound of formula V:



where R^3 , R^4 , R^7 , R^8 and Z are as defined in claim 19, and R^9 is C_1 - C_4 alkyl or C_1 - C_4 alkoxy.

10


22. A compound according to claim 11 which is a compound of formula VI:



where R^7 , R^8 and Z are as defined in claim 19 and R^{10} and R^{11} are independently selected from hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6 cycloalkyl, aryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl and aryloxy.

20


23. A compound according to claim 11 which is a compound of formula VII



30 where R^7 , R^8 and Z are as defined in claim 19 and R^{12} is hydrogen optionally substituted C_1 - C_6 alkyl, optionally substituted C_3 - C_7 cycloalkyl or optionally substituted aryl.


- 55 -

24. A compound according to claim 11 which is a compound of formula VIII:




where ϕ is optionally substituted aryl and R^7 , R^8 and Z are defined in claim 19.

10 25. A compound according to claim 11 which is a compound of formula IX:



where R^7 , R^8 and Z and ϕ are as defined in claim 24.

26. A compound according to claim 11 which is a compound of formula X:



25 where R^7 , R^8 , R^{12} and Z are as defined in claim 23 and ϕ is as defined in claim 24.

27. A compound according to any one of claims 24 to 26 where ϕ is phenyl or naphthyl either of which may have one to four substituents selected from hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6 cycloalkyl, aryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl and aryloxy.


30

- 56 -

28. A compound according to any one of claims 11 to 27 having a selectivity of greater than 3 over one or both of α_2 - and I_2 - receptors.
29. A compound according to any one of claims 11 to 28 having a selectivity for the
5 Ox receptor over both the α_2 - and I_2 - receptors of greater than 1.
30. A compound according to any one of claims 11 to 29 having a selectivity for the Ox receptor over the I_1 receptor of greater than 1.
- 10 31. A compound according to any one of claims 11 to 30 when used to bind to and/or modulate the activity of an Ox receptor.
32. A compound of any one of claims 11 to 30 which is an agonist of Ox receptor activity.
- 15 33. A compound of any one of claims 11 to 30 which is an antagonist of Ox receptor activity.
34. A modulator of Ox receptor activity which is a compound of any one of claims 11
20 to 30.
35. Use of a compound of any one of claims 11 to 30 to bind to and/or modulate the activity of Ox receptor.
- 25 36. A composition comprising a compound according to any one of claims 11 to 30 and a pharmaceutically acceptable carrier or diluent.
37. A method for the treatment or prevention of diseases of the central nervous system (excluding those involving CNS depressant action), cardiovascular system (excluding
30 hypertension), or of the kidney, or diseases associated with abnormal adrenal gland secretions or in the treatment of hyperglycaemia or peptic ulcer which comprises

- 57 -

administering an effective amount of a compound of formula II




wherein W is optionally substituted aryl, optionally substituted C₅-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-, or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof.

15

38. A method according to claim 38 wherein the disease of the central nervous system is selected from dementia, mood disturbances, degenerative conditions such as stroke or aging, ischaemia, CNS trauma, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

20

39. A method of the treatment or prevention of glaucoma comprising administering an effective amount of a compound of formula II



wherein W is optionally substituted aryl, optionally substituted C₅-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally

- 58 -

substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-; and

5 with the further provisos that

a) when Y is CH₂CH₂, X is O and Z is imino then

(i) if W is CHR¹R² and R¹ is H then R² is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; ~~or~~ 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and

(ii) if W is CHR¹R² and R¹ is CH₃ or cyclopropyl then R¹ is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and


b) when Y is (CH₂)₂₋₄, X is O or S, Z is imino and W is CHR¹R², then

(i) if R¹ is CF₃, CF₂CF₃ or CF₂CF₂CF₃ then R² is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R¹ is optionally substituted cyclopropyl, R² is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.

20 40. Use of a compound of formula II



II

25

wherein W is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally

30 substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-, or a pharmaceutically

- 59 -


acceptable salt or ester thereof, in the manufacture of a medicament for the prevention or treatment of diseases of the central nervous system (excluding those involving CNS depressant action), cardiovascular system (excluding hypertension), or of the kidney, or diseases associated with abnormal adrenal gland secretions or in the treatment of

5 hyperglycaemia or peptic ulcer.

41 Use according to claim 40 wherein the disease of the central nervous system is selected from dementia, mood disturbances, degenerative conditions such as stroke or aging, ischaemia, CNS trauma, and neurodegenerative diseases such as Alzheimer's

10 disease and Parkinson's disease.

42. Use of a compound of formula II



wherein W is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆

20 alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-; and with the further

25 proviso that

- a) when Y is CH₂CH₂, X is O and Z is imino then
 - (i) if W is CHR¹R² and R¹ is H then R² is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; or 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or
 - 30 2,6-dimethylphenyl; and
 - (ii) if W is CHR¹R² and R¹ is CH₃ or cyclopropyl then R¹ is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and
- b) when Y is (CH₂)₂₋₄, X is O or S, Z is imino and W is CHR¹R², then

- 60 -

- (i) if R^1 is CF_3 , CF_2CF_3 or $CF_2CF_2CF_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and
- (ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

5 or a pharmaceutically acceptable ester or salt thereof;

in the manufacture of a medicament for the prevention or treatment of glaucoma.

43. Use of a compound of any one of claims 11 to 30 in the manufacture of a
10 medicament for the treatment of diseases of the central nervous system, cardiovascular system, or the kidney, or diseases associated with abnormal adrenal gland secretions, or in the treatment or prevention of hyperglycaemia, glaucoma, peptic ulcer or in the production of analgesia.

15 44 Use of a compound of any one of claims 11 to 30 or a pharmaceutically acceptable salt or ester thereof in the prevention or treatment of diseases of the central nervous system, cardiovascular system, or the kidney, or diseases associated with abnormal adrenal gland secretions or in the treatment or prevention of hyperglycaemia, glaucoma, peptic ulcer or in the production of analgesia.

20

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name: that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled

RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS

[x] International Patent Application No PCT/AU98/00919 filed on 5 November 1998

which application is:

☐ the attached application
(for original application)

☐ application Serial No. _____
filed _____, and amended on _____

(for declaration not accompanying application)

that I have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware which is material to the patentability of this application under 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119, §172 or §365 of any provisional application or foreign application(s) for patent or inventor's certificate listed below and have also identified on said list any foreign application for patent or inventor's certificate on this invention having a filing date before that of any foreign application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed (yes or no)
PP 0202	Australia	5 November 1997	Yes


I hereby claim the benefit of Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application under 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending, abandoned)

I hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603 and George F. Lehnigk, Reg. No. 36,359 my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date 15/6/00 First Inventor William J. Louis
Residence Rosanna, Victoria Australia First Name Middle Initial Last Name
Signature X
Post Office Address P.O.Box 21, Rosanna, Victoria 3084, Australia
Citizenship Australian



00560560 07100

Date 15.6.00 2-00
Second Inventor Graham P. Jackman
Residence N. Clayton, Victoria Australia
Signature [Signature]
Post Office Address: 152 Ferntree Gully Road, North Clayton, Victoria 3168, Australia AUX
Citizenship Australian

Date 15/06/00 3-00
Third Inventor Elizabeth L. Conway
Residence Australia
Signature [Signature]
Post Office Address: 11 Goodall Street, Hawthorn, Victoria 3122, Australia AUX
Citizenship Australian

Date 15/06/00 4-00
Fourth Inventor Andrew L. Gundlach
Residence Hawthorn, Victoria
Signature [Signature]
Post Office Address: 21 William Street Hawthorn Victoria 3122, Australia AUX
Citizenship Australia

Date 15/6/00 5-00
Fifth Inventor Dimitri Lakovidis
Residence Doncaster, Victoria
Signature [Signature]
Post Office Address: 183 Church Road, Doncaster, Victoria 3108, Australia AUX
Citizenship Australian

Date 15/6/00 6-00
Sixth Inventor Paul R. King
Residence Australia
Signature [Signature]
Post Office Address: 6 Mitchell Street, Brunswick, Victoria 3056, Australia AUX
Citizenship Australian

Date 15/6/00 7-00
Seventh Inventor Simon N.S. Louis
Residence Australia
Signature [Signature]
Post Office Address: 46 Fergie Street, North Fitzroy, Victoria 3068, Australia AUX
Citizenship Australian

Date 15/6/00 8-00
Eighth Inventor Tracy Nero
Residence St. Albans, Victoria
Signature [Signature]
Post Office Address: 42 Oberon Avenue, St. Albans, Victoria 3021, Australia AUX
Citizenship Australian

00550807 073100

Date X _____ Second Inventor Graham P. Jackman
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 152 Ferntree Gully Road, North Clayton, Victoria 3168, Australia
Citizenship Australian

Date X 16/06/2000 Third Inventor Elizabeth L. Conway
First Name Middle Initial Last Name
Residence Australia Signature Elizabeth L Conway
Post Office Address: 11 Goodall Street, Hawthorn, Victoria 3122, Australia
Citizenship Australian

Date X _____ Fourth Inventor Andrew L. Gundlach
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 546 Barkers Road, Hawthorn East, Victoria 3123, Australia
Citizenship Australia

Date X _____ Fifth Inventor Dimitri Iakovidis
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 183 Church Road, Doncaster, Victoria 3108, Australia
Citizenship Australian

Date X _____ Sixth Inventor Paul R. King
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 6 Mitchell Street, Brunswick, Victoria 3056, Australia
Citizenship Australian

Date X _____ Seventh Inventor Simon N.S. Louis
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 46 Fergie Street, North Fitzroy, Victoria 3068, Australia
Citizenship Australian

Date X _____ Eighth Inventor Tracy Nero
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 42 Oberon Avenue, St Albans, Victoria 3021, Australia
Citizenship Australian

00120 20000550

Date X Second Inventor Graham P. Jackman
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 152 Ferntree Gully Road, North Clayton, Victoria 3168, Australia
Citizenship Australian

Date X Third Inventor Elizabeth L. Conway
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 11 Goodall Street, Hawthorn, Victoria 3122, Australia
Citizenship Australian

Date X Fourth Inventor Andrew L. Gundlach
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 546 Barkers Road, Hawthorn East, Victoria 3123, Australia
Citizenship Australia

Date X Fifth Inventor Dimitri Iakovidis
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 183 Church Road, Doncaster, Victoria 3108, Australia
Citizenship Australian

Date X 20.6.60 Sixth Inventor Paul R. King
First Name Middle Initial Last Name
Residence Brunswick, Victoria
Australia Signature Paul King
Post Office Address: 6 Mitchell Street, Brunswick, Victoria 3056, Australia
Citizenship Australian

Date X Seventh Inventor Simon N.S. Louis
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 46 Fergie Street, North Fitzroy, Victoria 3068, Australia
Citizenship Australian

Date X Eighth Inventor Tracy Nero
First Name Middle Initial Last Name
Residence Australia Signature X
Post Office Address: 42 Oberon Avenue, St Albans, Victoria 3021, Australia
Citizenship Australian

007620/0002560

Date Second Inventor Graham P. Jackman
 Residence Australia Signature X
 Post Office Address: 152 Ferntree Gully Road, North Clayton, Victoria 3168, Australia
 Citizenship Australian

Date Third Inventor Elizabeth L. Conway
 Residence Australia Signature
 Post Office Address: 11 Coodall Street, Hawthorn, Victoria 3122, Australia
 Citizenship Australian

Date Fourth Inventor Andrew L. Gundlach
 Residence Australia Signature X
 Post Office Address: 346 Barkers Road, Hawthorn East, Victoria 3123, Australia
 Citizenship Australia

Date Fifth Inventor Dimitri Iakovidis
 Residence Australia Signature
 Post Office Address: 183 Church Road, Doncaster, Victoria 3108, Australia
 Citizenship Australian

Date Sixth Inventor Paul R. King
 Residence Australia Signature X
 Post Office Address: 6 Mitchell Street, Brunswick, Victoria 3056, Australia
 Citizenship Australian

Date X 11/7/00 Seventh Inventor Simon N.S. Louis
 Residence N. Fitzroy, Victoria Australia Signature X
 Post Office Address: 46 Fergie Street, North Fitzroy, Victoria 3068, Australia
 Citizenship Australian

Date X Eighth Inventor Tracy Nero
 Residence Australia Signature X
 Post Office Address: 42 Oberon Avenue, St Albans, Victoria 3021, Australia
 Citizenship Australian

001620 20805500

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

William J. LOUIS et al.

Appl. No. 09/530,807

Filed: May 05, 2000



Group Unit:

For: RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE CLASS

SUBMISSION OF EXECUTED DECLARATIONAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the NOTICE OF MISSING REQUIREMENTS dated May 30, 2000 (copy enclosed) for the above identified application, Applicant submits herewith a duly executed Declaration together with a check in the late filing fee of \$130. Acknowledgement of the receipt of the above identified Declaration is respectfully requested. The Patent Office is authorized to charge any necessary fees to Deposit Account No. 19-4880 in order to keep the above identified application in force. A duplicate copy of this Paper is attached.

08/02/2000 ERINAND0 00000040 09530807

01 FC:154
02 FC:115130.00 OP
110.00 OP

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
Phone: (202) 293-7060
Fax: (202) 293-7860

Docket No: Q-59123

Respectfully submitted,

Richard C. Turner
Registration No. 29,710 for
Robert V. Sloan
Registration No. 22,775

Date: July 31, 2000